Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation
31.5.2024 09:00:00 EEST | Business Wire | Press release
Thermo Fisher Scientific Inc., the world leader in serving science, announced today that the Applied Biosystems™ CytoScan™ Dx Assay and Applied Biosystems™ Chromosomal Analysis Suite (ChAS) Dx software now comply with In Vitro Diagnostic Regulations (IVDR) 2017/746 in the European Union. These compliance updates will enable cytogenetics testing laboratories to adapt to the latest medical device safety and efficacy frameworks and conformity assessments.
“Thermo Fisher’s unparalleled commitment to driving innovation in chromosomal microarrays has led to advancement of cytogenetic testing capabilities,” said Kevin Lowitz, vice president and general manager, microarray, at Thermo Fisher Scientific. “The compliance updates to the CytoScan Dx Assay kit and ChAS Dx software provide our customers in the EU with solutions that can help them maintain high patient safety standards and meet EU IVD regulatory requirements.”
Advancements in chromosomal microarrays (CMAs) have greatly expanded the capabilities of cytogenetics testing in recent years, including the ability to yield insights into genetic risk factors and disorders that are essential to understanding reproductive health. As an in vitro diagnostic CMA test for postnatal analysis, the CytoScan Dx Assay aids in the identification of underlying genetic causes of neurological and dysmorphic disorders in children. The assay enables users to accurately detect numerous chromosomal variations at higher resolution and greater coverage than conventional methods. It has demonstrated to improve diagnostic yield by an incremental 12.5% compared to G-banded karyotyping.
ChAS Dx is a powerful, intuitive software that simplifies cytogenetic analysis, visualization, and reporting of chromosomal aberrations across the genome. ChAS Dx provides whole-genome support for CytoScan Dx Arrays with flexible parameters and data formats, as well as direct access to multiple leading external genetic databases. The advanced data analysis software is available to all CytoScan Dx customers at no additional cost.
The complete IVDR compliant CytoScan Dx Cytogenetics Suite is a sample to insight solution that includes the CytoScan Dx Array, a reagent kit, the Applied Biosystems™ GeneChip™ System 3000 Dx platform for array processing, and user-friendly ChAS Dx software.
To learn more about the complete IVDR compliant CytoScan Cytogenetics Suite, please visit www.thermofisher.com/microarrayivd.
For In Vitro Diagnostic Use.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530659960/en/
Contact information
Amanda Strickland
Thermo Fisher Scientific
Phone: +1 510-566-8921
E-mail: Amanda.strickland@ppd.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026: Food Sovereignty, AI, Personalised Nutrition… Three Major Debates to Shape the Future of Food14.10.2026 10:35:00 EEST | Press release
More than just a major business event, SIAL Paris is also a forum for reflection, analysis and inspiration for the entire food sector. Over five days, several stages will bring together leaders, experts, manufacturers, retailers, researchers and entrepreneurs to analyse the sector’s transformations and, above all, to identify concrete courses of action. Food sovereignty, artificial intelligence, geopolitics, new consumption models, personalised nutrition and the transformation of the value chain: the 2026 edition offers a particularly rich programme, featuring conferences, keynote speeches, round-table discussions, pitches and case studies. SIAL Summits: three major events to understand today and prepare for tomorrow At the heart of this programme, the SIAL Summits, held in Hall 5A, offer three premium 2½-hour sessions dedicated to the strategic challenges reshaping the agri-food industry. Designed as genuine platforms for discussion and reflection, they will bring together experts and
Otometrics Launches Aurical® IQ – Delivering the First and Only Guided Workflow Enabling up to 51% Faster Fittings and 39% Improved Workflow Accuracy14.10.2026 10:00:00 EEST | Press release
Otometrics, the Hearing & Balance division of Natus Sensory, today announced Aurical® IQ, the next generation of its trusted hearing aid fitting and verification platform. Combining the first and only Guided Workflow for hearing aid fitting and verification, support for the NAL-NL3 Fitting System and a redesigned Otosuite® software experience, Aurical IQ is designed to help hearing care professionals work more efficiently and follow best-practice fitting procedures with greater consistency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014023398/en/ Aurical IQ Guided Workflow provides structured, step-by-step guidance through the fitting and verification process, designed to make best-practice fitting easier to follow. A new chapter of innovation for Otometrics Clinical evaluations demonstrated measurable benefits for clinicians at different levels of experience. Experienced clinicians achieved up to 51% faster fitting t
NEURA Robotics Introduces Neuron AI: The Brain of the Physical World14.10.2026 09:29:00 EEST | Press release
NEURA Robotics (“NEURA”) today introduced Neuron AI, its multimodal foundation model for Physical AI. Combining 3D vision, touch, audio, robot state and language with memory, Neuron AI enables robots to act on information beyond what cameras alone can capture, as well as retain relevant context when objects disappear from view. Its Perception-Language-Action (PLA) architecture connects what a robot sees, hears and feels with what it has already done, turning multisensory information into physical action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013482085/en/ Neuron AI: The Brain of the Physical World “An intelligent robot needs a brain that brings its senses together and remembers what happened,” said David Reger, Founder and CEO of NEURA Robotics. “With Neuron AI, we are building the brain of the physical world: Physical AI that turns human expertise and physical experience into capabilities robots can learn and ap
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering14.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built on clinical science and protocol-based daily care, from its shareholders, including funds managed by Blackstone Tactical Opportunities (“Blackstone”) and the Obagi family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013945338/en/ Founded by dermatologist Dr. Zein Obagi and headquartered in Irvine, California, ZO Skin Health has been a reference name in clinically-backed professional skincare for more than two decades. Its broad product portfolio, spanning over 40 products, is manufactured in the U.S. and sold through a network of more than 16,500 physician, medical spa and online accounts across more than 40 countries, supported by a dedicated salesforce and skincare education team. ZO Skin Health recorded net sales of approximately 330 million USD in the last twelve months
Pretium Expands Middle East Presence with Abu Dhabi Office14.10.2026 07:02:00 EEST | Press release
Pretium, a specialized investment firm with approximately $70 billion in assets under management1, today announced the opening of an office in Abu Dhabi. The office will operate within Abu Dhabi Global Market (“ADGM”), the international financial center of Abu Dhabi, providing proximity to some of the world’s leading institutional investors. The Abu Dhabi office marks an important step in the continued evolution of Pretium’s business. From its roots in U.S. residential real estate, Pretium has built a scaled investment platform spanning real estate equity and credit. A dedicated presence in Abu Dhabi will enhance the Firm’s connections to clients in the region as it continues to develop new investment solutions. “Abu Dhabi is home to some of the world’s most sophisticated and forward-looking institutional investors,” said Don Mullen, Founder and CEO of Pretium. “An on-the-ground presence here will enable us to spend more time alongside our partners in the region and help expand their i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom